Table 1.
Clinical and laboratory parameters
| NODAT group | Non-NODAT group | P | |
| No. of patients | 34 (27.2%) | 91 (72.8%) | |
| Age at transplant (yr) | 49.6 ± 10.8 | 46.0 ± 13.6 | 0.165 |
| Female sex | 53% (18/34) | 47% (43/91) | 0.571 |
| Race Caucasian African | 70.6% (24/34) 29.4% (10/34) | 78% (71/91) 22% (20/91) | 0.387 |
| Body mass index (kg/m2) | 25.2 ± 4.0 | 24.5 ± 4.4 | 0.418 |
| Pre-transplant FPG (mg/dL) | 101 (96.1-105.7) | 92 (91.4-95.8) | 0.007 |
| Pretransplant IFG | 51.5% (17/33) | 27.7% (23/83) | 0.01 |
| Hepatitis C infection | 2.9% (1/34) | 1.1% (1/91) | 0.472 |
| CMV infection | 97% (33/34) | 93% (82/88) | 0.672 |
| Acute rejection | 14.7% (5/34) | 8.8% (8/91) | 0.338 |
| Type of transplant Deceased donor Living donor | 100% (34/34) 0% (0/34) | 91.2% (83/91) 8.8 % (8/91) | 0.106 |
| Follow-up (mo) | 36.4 ± 2.5 | 35.5 ± 1.6 | 0.774 |
CMV: Cytomegalovirus; FPG: Fasting plasma glucose; IFG: Impaired fasting glucose; NODAT: New-onset diabetes after transplantation.